User Guide Mercury Arsenic and Cadmium Toxicity in Children
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Industry Compliance Programme
Global Chemical Industry Compliance Programme GC-ICP Chemical Weapons Convention December 2006 Version 1.0 GLOBAL CHEMICAL INDUSTRY COMPLIANCE PROGRAMME FOR IMPLEMENTING THE CHEMICAL WEAPONS CONVENTION The purpose of the handbook is to provide guidance to chemical facilities, traders and trading companies in developing a Global Chemical Industry Compliance Programme (GC-ICP) to comply with the Chemical Weapons Convention (CWC). The GC-ICP focuses first on determining if there is a reporting requirement to your National Authority and second on collecting the relevant support data used to complete the required reports. The GC-ICP is designed to provide a methodology to comply with the CWC and establish systems that facilitate and demonstrate such compliance. Each facility/company should also ensure that it follows its country’s CWC specific laws, regulations and reporting requirements. • Sections 2, 3, and 4 guide you through the process of determining if chemicals at your facility/ company should be reported to your National Authority for compliance with the CWC. • Section 5 provides recommended guidance on information that you may use to determine your reporting requirements under the CWC and administrative tools that your facility/company may use to ensure compliance with the CWC. • Section 6 provides a glossary of terms and associated acronyms. • Section 7 provides a listing of all National Authorities by country. CWC Global Chemical Industry Compliance Programme 1 TABLE OF CONTENTS Section 1 Overview What is the Chemical Weapons Convention? -
PVC) Products ______
CPSC Staff Report on Lead and Cadmium in Children's Polyvinyl Chloride (PVC) Products ___________________________________________ 21 November 1997 U.S. Consumer Product Safety Commission Washington, D.C. 20207 CPSC Staff Report on Lead and Cadmium in Children's Polyvinyl Chloride (PVC) Products November 1997 I. Introduction Since its inception, the U.S. Consumer Product Safety Commission (CPSC) has played a prominent role in protecting the public, especially children, from the hazards of exposure to lead and other toxic chemicals. The CPSC has a strong record of removing products from the marketplace that contain lead and result in exposures that are hazardous to children. Just this past year, Commission action resulted in manufacturers eliminating the use of lead as a stabilizer in vinyl miniblinds, stopping the production of children's jewelry containing lead, and developing and distributing guidance to state health officials and others about lead paint on public playground equipment. Several years ago, CPSC recalled crayons that contained hazardous levels of lead. The Commission is continually screening toys for the presence of lead paint and has recalled many toys that violated the Commission's lead paint standard. In 1996, CPSC found that children could be exposed to hazardous levels of lead in imported non-glossy vinyl (polyvinyl chloride, PVC) miniblinds. Following this discovery, CPSC staff collected and tested a number of children's plastic products that they believed might be repeatedly exposed to sunlight and heat such as the vinyl miniblinds. This type of exposure was shown by CPSC staff to promote the deterioration of the lead-containing PVC miniblind slats and result in the formation of lead dust on the slats' surface. -
Responding to a Chemical Warfare Agent Incident: from Sampling and Analysis to Decontamination and Waste Management Stuart Willi
Responding to a Chemical Warfare Agent Incident: from sampling and analysis to decontamination and waste management Stuart Willison & Lukas Oudejans U. S. EPA National Homeland Security Research Center 1 Outline • Homeland Security Relevance to Chemical (Warfare Agent) Incidents and Incident Response Cycle • Identification of Gaps/Needs: PARTNER Process and Stakeholder Priorities • Current High Stakeholder Priorities • Research Efforts to meet these Needs/Gaps Selected Analytical Methods (SAM) Document CWA Method Development and Wipe Efficiency Studies on Surfaces Fate and Transport of CWAs Natural Attenuation of VX Decontamination of Vesicant/Blister CWAs HD, L, HL Analytical Method Development: Lewisite; EA 2192 Best Practices Document for Waste Media from Remediation Activities • Summary 2 Response to Contamination Events Since 9/11, multiple chemical/biotoxin contamination events have occurred in the United States and worldwide: • Several ricin incidents (2002-2014) • Deepwater Horizon oil spill (April 2010) • Kalamazoo River oil spill (July 2010) • CWA sulfur mustard clam shells (2010) • CWA chemical attacks (Syria, Middle East) (March-August 2013 and April 2014-current) • Elk River chemical spill in West Virginia (January 2014) • Toxic algae blooms in Toledo, OH (August 2014) • Arsenic-contaminated soil in Kentucky potentially containing CWA Lewisite (March 2015) • (Organophosphate-) Pesticide over- or misuse across USA in relation to bed bug epidemic (current) 3 Response Cycle Contaminant Release Reduce Vulnerabilities Lessons -
Health Concerns of Heavy Metals (Pb; Cd; Hg) and Metalloids (As)
Health concerns of the heavy metals and metalloids Chris Cooksey • Toxicity - acute and chronic • Arsenic • Mercury • Lead • Cadmium Toxicity - acute and chronic Acute - LD50 Trevan, J. W., 'The error of determination of toxicity', Proc. Royal Soc., 1927, 101B, 483-514 LD50 (rat, oral) mg/kg CdS 7080 NaCl 3000 As 763 HgCl 210 NaF 52 Tl2SO4 16 NaCN 6.4 HgCl2 1 Hodge and Sterner Scale (1943) Toxicity Commonly used term LD50 (rat, oral) Rating 1 Extremely Toxic <=1 2 Highly Toxic 1 - 50 3 Moderately Toxic 50 - 500 4 Slightly Toxic 500 - 5000 5 Practically Non-toxic 5000 - 15000 6 Relatively Harmless >15000 GHS - CLP LD50 Category <=5 1 Danger 5 - 50 2 Danger 50 - 300 3 Danger 300 - 2000 4 Warning Globally Harmonised System of Classification and Labelling and Packaging of Chemicals CLP-Regulation (EC) No 1272/2008 Toxicity - acute and chronic Chronic The long-term effect of sub-lethal exposure • Toxicity - acute and chronic • Arsenic • Mercury • Lead • Cadmium Arsenic • Pesticide o Inheritance powder • Taxidermy • Herbicide o Agent Blue • Pigments • Therapeutic uses Inorganic arsenic poisoning kills by allosteric inhibition of essential metabolic enzymes, leading to death from multi- system organ failure. Arsenicosis - chronic arsenic poisoning. Arsenic LD50 rat oral mg/kg 10000 1000 LD50 100 10 1 Arsine Arsenic acid Trimethylarsine Emerald green ArsenicArsenious trisulfide oxideSodium arsenite MethanearsonicDimethylarsinic acid acid Arsenic poisoning by volatile arsenic compounds from mouldy wall paper in damp rooms • Gmelin (1839) toxic mould gas • Selmi (1874) AsH3 • Basedow (1846) cacodyl oxide • Gosio (1893) alkyl arsine • Biginelli (1893) Et2AsH • Klason (1914) Et2AsO • Challenger (1933) Me3As • McBride & Wolfe (1971) Me2AsH or is it really true ? William R. -
Chelation Therapy
Medical Policy Chelation Therapy Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History Policy Number: 122 BCBSA Reference Number: 8.01.02 NCD/LCD: N/A Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Chelation therapy in the treatment of the following conditions is MEDICALLY NECESSARY: • Extreme conditions of metal toxicity • Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to nontransfusion-dependent thalassemia (NTDT) • Wilson's disease (hepatolenticular degeneration), or • Lead poisoning. Chelation therapy in the treatment of the following conditions is MEDICALLY NECESSARY if other modalities have failed: • Control of ventricular arrhythmias or heart block associated with digitalis toxicity • Emergency treatment of hypercalcemia. NaEDTA as chelation therapy is considered NOT MEDICALLY NECESSARY. Off-label applications of chelation therapy are considered INVESTIGATIONAL, including, but not limited to: • Alzheimer’s disease • Arthritis (includes rheumatoid arthritis) • Atherosclerosis, (e.g., coronary artery disease, secondary prevention in patients with myocardial infarction, or peripheral vascular disease) • Autism • Diabetes • Multiple sclerosis. 1 Prior Authorization Information Inpatient • For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient. Outpatient • For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient. Outpatient Commercial Managed Care (HMO and POS) Prior authorization is not required. Commercial PPO and Indemnity Prior authorization is not required. Medicare HMO BlueSM Prior authorization is not required. -
Veterinary Toxicology
GINTARAS DAUNORAS VETERINARY TOXICOLOGY Lecture notes and classes works Study kit for LUHS Veterinary Faculty Foreign Students LSMU LEIDYBOS NAMAI, KAUNAS 2012 Lietuvos sveikatos moksl ų universitetas Veterinarijos akademija Neužkre čiam ųjų lig ų katedra Gintaras Daunoras VETERINARIN Ė TOKSIKOLOGIJA Paskait ų konspektai ir praktikos darb ų aprašai Mokomoji knyga LSMU Veterinarijos fakulteto užsienio studentams LSMU LEIDYBOS NAMAI, KAUNAS 2012 UDK Dau Apsvarstyta: LSMU VA Veterinarijos fakulteto Neužkre čiam ųjų lig ų katedros pos ėdyje, 2012 m. rugs ėjo 20 d., protokolo Nr. 01 LSMU VA Veterinarijos fakulteto tarybos pos ėdyje, 2012 m. rugs ėjo 28 d., protokolo Nr. 08 Recenzavo: doc. dr. Alius Pockevi čius LSMU VA Užkre čiam ųjų lig ų katedra dr. Aidas Grigonis LSMU VA Neužkre čiam ųjų lig ų katedra CONTENTS Introduction ……………………………………………………………………………………… 7 SECTION I. Lecture notes ………………………………………………………………………. 8 1. GENERAL VETERINARY TOXICOLOGY ……….……………………………………….. 8 1.1. Veterinary toxicology aims and tasks ……………………………………………………... 8 1.2. EC and Lithuanian legal documents for hazardous substances and pollution ……………. 11 1.3. Classification of poisons ……………………………………………………………………. 12 1.4. Chemicals classification and labelling ……………………………………………………… 14 2. Toxicokinetics ………………………………………………………………………...………. 15 2.2. Migration of substances through biological membranes …………………………………… 15 2.3. ADME notion ………………………………………………………………………………. 15 2.4. Possibilities of poisons entering into an animal body and methods of absorption ……… 16 2.5. Poison distribution -
Supplement to All Hazards Receipt Facility (AHRF) Screening Protocol
EPA/600/R-10/155 December 2010 Supplement to All Hazards Receipt Facility (AHRF) Screening Protocol SCIENCE Office of Research and Development National Homeland Security Research Center Supplement to All Hazards Receipt Facility (AHRF) Screening Protocol December 2010 Office of Research and Development National Homeland Security Research Center Acknowledgments This document is intended to be supplementary to the U.S. Environmental Protection Agency (EPA) and U.S. Department of Homeland Security (DHS) September 2008 All Hazards Receipt Facility Protocol (AHRF Protocol), and attempts to address considerations raised by stakeholders since publication of the protocol. Development of this document was funded by the U.S. Environmental Protection Agency (EPA) National Homeland Security Research Center (NHSRC), and includes information provided by EPA Regions 1, 6, and 10; EPA Office of Radiation and Indoor Air (ORIA), the Association of Public Health Laboratories (APHL): State Public Health Laboratories of Connecticut, Delaware, Massachusetts, Minnesota, New Jersey, New York, and Virginia; and New York City; and the Canadian Defence Research and Development Laboratory. This document was prepared by CSC under Contract EP-W-06- 046. Disclaimer This document is intended to be supplementary to the guidance provided in the U.S. Environmental Protection Agency (EPA) and U.S. Department of Homeland Security (DHS) September 2008 All Hazards Receipt Facility Protocol (AHRF Protocol), and attempts to address considerations raised by stakeholders since publication of the protocol. This supplement assumes that: • The September 2008 AHRF Protocol was developed and provided as a guide; implementation of the protocol and the screening equipment included in the protocol may vary among locations, depending on the goals and capabilities of the laboratory to which the facility is attached. -
A Pilot Study in Detoxification of Heavy Metals
The Role of Heavy Metal Detoxification in Heart Disease and Cancers : A Pilot Study in Detoxification of Heavy Metals Daniel Dugi, M.D. Sir Arnold Takemoto Presented at the WESCON Biomedicine and Bioengineering Conference Anaheim Convention Center The Future of Medicine Afternoon Session September 24, 2002 Anaheim, California USA 1 ABSTRACT Heavy metal detoxification has been shown to decrease cancer mortality by 90% in a 18-year controlled clinical study by Blumer and Cranton. Frustachi et. al. has shown a very strong correlation between cardiomyopathy (heart disease) and heavy metals accumulation in the coronary arteries and heart muscle. The role of heavy metal detoxification in the prevention and/or treatment of cancers and heart disease is paramount for optimum healing or prevention. Heavy metal accumulation can cause suppression of the immune system, bind receptor sites, inhibit proper enzyme systems, and lead to undesirable free-radical and oxidative functions. A pilot study utilizing a unique oral detoxifying concentrate, DeTox Max, containing true disodium EDTA, microencapsulated in essential phospholipids microspheres was utilized as a provocation, detoxifying agent for a 16 patient pilot study. Significant quantities of heavy metals were excreted in a 48-hour collection versus each patient’s baseline 24 hour collection. The pilot study results confirmed substantial excretion of heavy metals. A surprising outcome of the study was the remarkable clinical healing and significant increase in brain acuity in patients that occurred within 2 weeks after only one vial was utilized, compared to previous pre - provocation. 2 Detox MAX Clinical Study Proposal ¾ To assess the heavy metal detoxifying ability of Detox MAX, an oral detoxification agent containing 22 grams of essential phospholipids (EPL’s); micro- encapsulating 1 gram of sodium endetate. -
Plovdiv Medical Faculty
MEDICAL UNIVERSITY – PLOVDIV MEDICAL FACULTY SECOND DEPARTMENT OF INTERNAL MEDICINE SECTION OF OCCUPATIONAL DISEASES AND TOXICOLOGY PROGRAMME FOR OCCUPATIONAL DISEASES AND TOXICOLOGY CURRICULUM - MEDICAL SPECIALTY Accepted by the Department Council with protocol № 39/30.01.2020 Approved by the Faculty Council on 08.07.2020 CURRICULUM Hours in Exam in Discipline Hours years and semester semester Practical Occupational Everything Lectures Credits exercises Diseases and VI Toxicology 45 15 30 2 1/2 VI Name of the discipline: OCCUPATIONAL DISEASES AND TOXICOLOGY Type of discipline according to unified state requirements: Obligatory Level of education: Master /M/ Forms of education: Lectures, exercises, self-preparation. Training course: 3rd year Duration of training: One semester Horarium: 15 hours lectures, 30 hours practical exercises Teaching aids: Multimedia products; audio-visual materials; authentic materials, posters, medical history, projects, tables, diagrams, and other non-verbal visuals, consistent with the lectures and exercises’ topics; discussions; demonstration of clinical cases and diagnostic methods and devices; clinical data and paraclinical studies for diagnosis and interpretation; therapeutic agents and schematics of nosological units; normative documents on occupational diseases related to the disclosure of recognition procedure for the occupational origin of certain disease, criteria for occupational origin based diagnosis of diseases, list of occupational diseases, etc .; practical situational tasks; reference materials for developing students' skills for individual practice; thematic referrals; preventive programmes. Assessment forms: tests, discussing the topic of the practical exercise, solving clinical cases, writing an essay Formation of the mark: The assessment is formed of current semester academic control Assessment aspects: Participation in discussions, solving clinical cases, tests, writing an essay Semester examination: Yes / Entry Test, Written and Oral Exam. -
Chelation Therapy
Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder. -
Adverse Health Effects of Heavy Metals in Children
TRAINING FOR HEALTH CARE PROVIDERS [Date …Place …Event …Sponsor …Organizer] ADVERSE HEALTH EFFECTS OF HEAVY METALS IN CHILDREN Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization www.who.int/ceh October 2011 1 <<NOTE TO USER: Please add details of the date, time, place and sponsorship of the meeting for which you are using this presentation in the space indicated.>> <<NOTE TO USER: This is a large set of slides from which the presenter should select the most relevant ones to use in a specific presentation. These slides cover many facets of the problem. Present only those slides that apply most directly to the local situation in the region. Please replace the examples, data, pictures and case studies with ones that are relevant to your situation.>> <<NOTE TO USER: This slide set discusses routes of exposure, adverse health effects and case studies from environmental exposure to heavy metals, other than lead and mercury, please go to the modules on lead and mercury for more information on those. Please refer to other modules (e.g. water, neurodevelopment, biomonitoring, environmental and developmental origins of disease) for complementary information>> Children and heavy metals LEARNING OBJECTIVES To define the spectrum of heavy metals (others than lead and mercury) with adverse effects on human health To describe the epidemiology of adverse effects of heavy metals (Arsenic, Cadmium, Copper and Thallium) in children To describe sources and routes of exposure of children to those heavy metals To understand the mechanism and illustrate the clinical effects of heavy metals’ toxicity To discuss the strategy of prevention of heavy metals’ adverse effects 2 The scope of this module is to provide an overview of the public health impact, adverse health effects, epidemiology, mechanism of action and prevention of heavy metals (other than lead and mercury) toxicity in children. -
The Deactivation of Industrial SCR Catalysts—A Short Review
energies Review The Deactivation of Industrial SCR Catalysts—A Short Review Agnieszka Szymaszek *, Bogdan Samojeden * and Monika Motak * Faculty of Energy and Fuels, AGH University of Science and Technology, Al. Mickiewicza 30, 30-059 Kraków, Poland * Correspondence: [email protected] (A.S.); [email protected] (B.S.); [email protected] (M.M.) Received: 2 July 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: One of the most harmful compounds are nitrogen oxides. Currently, the common industrial method of nitrogen oxides emission control is selective catalytic reduction with ammonia (NH3-SCR). Among all of the recognized measures, NH3-SCR is the most effective and reaches even up to 90% of NOx conversion. The presence of the catalyst provides the surface for the reaction to proceed and lowers the activation energy. The optimum temperature of the process is in the range of 150–450 ◦C and the majority of the commercial installations utilize vanadium oxide (V2O5) supported on titanium oxide (TiO2) in a form of anatase, wash coated on a honeycomb monolith or deposited on a plate-like structures. In order to improve the mechanical stability and chemical resistance, the system is usually promoted with tungsten oxide (WO3) or molybdenum oxide (MoO3). The efficiency of the commercial V2O5-WO3-TiO2 catalyst of NH3-SCR, can be gradually decreased with time of its utilization. Apart from the physical deactivation, such as high temperature sintering, attrition and loss of the active elements by volatilization, the system can suffer from chemical poisoning. All of the presented deactivating agents pass for the most severe poisons of V2O5-WO3-TiO2.